Mirum Pharmaceuticals, Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation and amortization $139k $305k $595k $3.2m $10.8m $23.6m $24.2m
Amortization of debt discount and offering costs $0 $0 $1.1m $1.7m $1.7m
Non-cash interest expense related to the revenue interest liability $0 $335k $17.6m $16.0m $5.1m $0 $0
Operating lease liabilities ($51k) ($385k) ($649k) ($711k) ($940k) ($782k) ($1.9m)
Operating cash flows paid for operating lease $170k $576k $864k $911k $1.1m $1.3m $2.6m
Net loss ($52.6m) ($103.3m) ($84.0m) ($135.7m) ($163.4m) ($87.9m) ($23.4m)
Stock-based compensation $6.1m $12.6m $23.1m $27.0m $35.0m $48.4m $71.4m
Inventory reserves and firm commitment losses $0 $0 $9.3m $2.6m $2.9m
Loss from termination of revenue interest purchase agreement $0 $0 $49.1m $0 $0
Unrealized foreign exchange (gain) loss $0 $0 $1.8m ($1.2m) ($1.7m)
Non-cash lease expense $380k $443k $620k $1.4m $1.7m
Other ($3.5m) ($1.1m) ($795k) ($1.4m)
Accounts receivable $0 ($20.7m) ($44.0m) ($11.4m) ($48.1m)
Prepaid and other current assets ($2.7m) ($1.8m) ($4.0m) ($3.7m) ($3.6m) ($849k) ($5.8m)
Inventory $0 ($495k) ($3.4m) ($4.4m) ($3.2m) ($8.4m)
Other assets ($160k) ($954k) ($519k) ($127k) ($511k) ($1.5m) ($5.7m)
Accounts payable, accrued expenses and other liabilities $10.1m $3.7m $22.7m $7.6m $30.8m $40.3m $50.1m
Purchase of property and equipment ($281k) ($225k) ($24k) ($278k) ($109k) ($993k) ($954k)
Cash paid for acquisition $0 $0 ($212.8m) $0 $0
Payments made for additions to intangible assets ($19.0m) $0 ($20.0m) ($20.0m) $0
Proceeds from issuance of convertible notes, net $0 $0 $305.3m $0 $0
Payments of deferred offering costs $0 ($158k) $0 $0 ($281k) $0 $0
Payments on revenue interest liability $0 ($121k) ($5.6m) ($195.6m) $0 $0
Accrued milestone payments classified as intangible assets, net $0 $15.0m $0 $0 $35.0m
Right-of-use assets obtained in exchange for lease liabilities $3.7m $0 $0 $285k $473k $9.6m $2.4m
Decrease in ROU assets and lease liabilities due to lease modification $0 $0 $723k $649k
Stock-based compensation capitalized to inventory $71k $441k $822k $1.1m $688k
Conversion of convertible notes, net into shares of common stock $0 $0 $24k
Net cash provided by (used in) operating activities ($39.4m) ($89.1m) ($132.8m) ($120.1m) ($70.9m) $10.3m $55.8m
Purchase of investments ($152.0m) ($74.6m) ($198.0m) ($132.3m) ($27.3m) ($89.0m) ($97.4m)
Proceeds from maturities of investments $24.5m $85.9m $155.6m $140.3m $153.0m $19.9m $74.4m
Net cash used in investing activities ($127.8m) $37.9m $48.5m $7.7m ($107.2m) ($90.1m) ($24.0m)
Proceeds from issuance of common stock in private placement, net of issuance costs $0 $10.0m $0 $0 $202.2m $0 $0
Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs $0 $0 $21.3m $14.5m $0 $0
Proceeds from issuance of common stock pursuant to equity plans $0 $784k $2.1m $7.3m $10.5m $17.7m $40.1m
Issuance of common stock in connection with settlement of Contingent Milestone and Indemnification Holdback liabilities $0 $0 $5.2m $0 $0
Net cash provided by financing activities $127.2m $181.3m $73.5m $109.1m $336.6m $17.7m $40.1m
Effect of exchange rate on cash, cash equivalents and restricted cash ($27k) $29k ($1k) $12k ($133k) ($1.3m) $3.2m
Net increase (decrease) in cash, cash equivalents and restricted cash ($40.0m) $130.1m ($10.7m) ($3.3m) $158.3m ($63.4m) $75.2m
Cash, cash equivalents and restricted cash at beginning of period $12.0m $142.1m $131.3m $128.0m $286.3m $222.9m $298.2m
Cash paid for interest $0 $0 $6.8m $12.7m $12.7m
Cash paid for income taxes $21k $11k $0 $0 $125k $1.0m $2.2m